<DOC>
	<DOCNO>NCT00657410</DOCNO>
	<brief_summary>RATIONALE : Drugs , prednisone dexamethasone , may change immune system effective treatment primary immune thrombocytopenic purpura . It yet know drug effective treating primary immune thrombocytopenic purpura . PURPOSE : This randomized phase III trial study high-dose dexamethasone see well work compare standard-dose prednisone treat patient newly diagnose , previously untreated primary immune thrombocytopenic purpura .</brief_summary>
	<brief_title>Prednisone Dexamethasone Newly Diagnosed , Previously Untreated Primary Immune Thrombocytopenic Purpura</brief_title>
	<detailed_description>OBJECTIVES : Primary - To evaluate role therapy intensification adult patient newly diagnose , previously untreated primary immune thrombocytopenic purpura high-dose dexamethasone ( HD-DXM ) , term improvement response 6 month initial response , comparison standard-doses prednisone . Secondary - Compare rate initial response . - Compare quality response . - Compare rate final response rate persistent response . - Compare rate bleed event . - Determine rate resume response HD-DXM non-responder patient patient lose response ( arm I ) . - Compare time platelet number increase hemostatically effective level reach and/or disappearance bleeding symptom . - Compare rate rescue intervention . - Compare rate eligible patient splenectomy . - Compare rate patient underwent splenectomy . - Compare rate patient develop connective tissue disease underlie hematological disease ( myelodysplastic syndrome , chronic lymphoproliferative disease , others ) . - Compare patient 's self report quality life . OUTLINE : This multicenter study . Patients stratify treat center . Patients randomize 1 2 treatment arm . - Arm I ( Standard-dose prednisone ) : Patients receive oral prednisone standard dose ( 1 mg/Kg ) daily day 1-28 follow 14-day taper . Patients consider non-responders day 42 lose response evaluation final response ( day 180 ) cross arm II . - Arm II ( High-dose dexamethasone ) : Patients receive oral dexamethasone high dose ( 40 mg/day ) daily day 1-4 . Treatment repeat every 14 day 3 course . Quality life assess baseline , day 42 ( arm I ) 46 ( arm II ) ( initial response evaluation day ) , 180 day initial response evaluation , 3 , 9 , 12 month randomization . After completion study treatment , patient follow monthly 1 year randomization , every 2 month 1 year , every 3 month 1 year .</detailed_description>
	<mesh_term>Purpura , Thrombocytopenic</mesh_term>
	<mesh_term>Purpura</mesh_term>
	<mesh_term>Purpura , Thrombocytopenic , Idiopathic</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Inclusion criterion Signed write informed consent accord IGH/EU/GCP national local law Newly diagnose untreated ITP adult patient Age &gt; 18 &lt; 80 year Platelet count &lt; 20x109/L Platelet count &gt; 20 x109/L &lt; 50x109/L plus bleed score &gt; 8 ( accord grade scale paragraph 7.1 ) Baseline Quality Life evaluation questionnaire fill Newly diagnose untreated ITP adult patient Age &gt; 18 &lt; 80 year Platelet count &lt; 20x109/L Platelet count &gt; 20 x109/L &lt; 50x109/L plus bleed score &gt; 8 ( accord grade scale paragraph 7.1 ) Baseline Quality Life evaluation questionnaire fill Exclusion criterion Active malignancy time study entry Steroids administration ( PDN &lt; 1mg/Kg/day ) 5 day randomization Concomitant treatment antiplatelet anticoagulant drug Concomitant severe psychiatric disorder Not confirm diagnosis ITP *Positivity autoimmunity marker : antinucleus ( ≥1:80 ) , antitireoglobulin , antitireoperoxidase , anticardiolipin ( ≥ 40 GPL UmL ) , antib2glycoprotein ( ≥ 40 IgG U/mL ) antibody , Lupus Anticoagulant ( KCT ratio , dRVVT ratio ≥1.5 time upper normal limit ) , direct antiglobulin test ( DAT ) . Presence autoimmune hemolytic anemia Presence connective tissue disease Women pregnant breastfeed Cardiovascular disease require treatment Severe noncontrolled , despite therapy , hypertension diabetes Liver kidney function impairment ( creatinine , ALT , AST &gt; 2 time upper normal limit ) HCVAb , HIVAb , HBsAg , HBcAb seropositive status Chronic liver disease Documented viral illness positivity IgM , vaccination occur one month diagnosis Intake drug previously take within one week diagnosis Bleeding score 15 due ICH GI bleeding ( accord grade scale paragraph 7.1 , Tab . 3 ) Active gastric ulcer .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>idiopathic thrombocytopenic purpura</keyword>
</DOC>